261766-73-8 Usage
Molecular structure
2,3-dihydrobenzo[1,4]-dioxine-5-carboxylic acid 1-[3-(4-methylpiperazine-1-sulfonyl)propyl]piperidin-4-ylmethylamide is a complex organic compound that features a dihydrobenzodioxine ring, a carboxylic acid group, a piperidin-4-ylmethylamide moiety, and a 4-methylpiperazine-1-sulfonyl group.
Carboxylic acid group
The presence of a carboxylic acid group (-COOH) in the compound allows for hydrogen bonding and may contribute to its solubility in water. This functional group is also common in many pharmaceuticals and can be involved in drug-receptor interactions.
Sulfonyl group
The 4-methylpiperazine-1-sulfonyl group is a sulfonyl (-SO2) functional group attached to a 4-methylpiperazine ring. Sulfonyl groups are known to have various biological activities and can influence the pharmacokinetic and pharmacodynamic properties of a compound.
Potential pharmaceutical applications
Due to its unique structure and various functional groups, 2,3-dihydrobenzo[1,4]-dioxine-5-carboxylic acid 1-[3-(4-methylpiperazine-1-sulfonyl)propyl]piperidin-4-ylmethylamide may have potential pharmaceutical applications. However, further research is needed to fully understand its biological activity and potential uses.
Involvement in drug development and medicinal chemistry
The compound's structural characteristics and chemical properties make it a candidate for research in drug development and medicinal chemistry. Further study and analysis of its biological activity, pharmacokinetics, and pharmacodynamics are necessary to determine its potential applications in these fields.
Check Digit Verification of cas no
The CAS Registry Mumber 261766-73-8 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,6,1,7,6 and 6 respectively; the second part has 2 digits, 7 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 261766-73:
(8*2)+(7*6)+(6*1)+(5*7)+(4*6)+(3*6)+(2*7)+(1*3)=158
158 % 10 = 8
So 261766-73-8 is a valid CAS Registry Number.
261766-73-8Relevant articles and documents
Identification of a 5-HT4 receptor antagonist clinical candidate through side-chain modification
Clark, Robin D.,Jahangir, Alam,Alam, Muzaffar,Rocha, Cynthia,Lin, Lin,Bjorner, Bodil,Nguyen, Khanh,Grady, Carole,Williams, Timothy J.,Stepan, George,Tang, Hai Ming,Ford, Anthony P.D.W.
, p. 1697 - 1700 (2007/10/03)
Replacement of the N-butyl side-chain of lead 5-HT4 receptor antagonist 2 with propanesulfonylpiperidinyl, morpholinyl, and piperazinyl groups led to higher affinity analogs 4-6. In vitro drug metabolism screens and cassette pharmacokinetic studies in the dog led to identification of the N-methylpiperazinyl analog (6b), which displayed pharmacokinetic, selectivity, and safety parameters sufficient for advancement to the clinic for the treatment of urinary incontinence.
